StockDuty ← Dashboard Oct 30, 2026 12:56 AM ET
SignalFDA/Bio

Exelixis outlines March 3, 2027 PDUFA for zanza while advancing Wave 2 pivotal plans

Exelixis set a March 3, 2027 PDUFA for zanza and advanced Wave 2 pivotal plans.

What happened: Exelixis outlined a March 3, 2027 PDUFA date for zanzalintinib while advancing Wave 2 pivotal plans, per its Q3 2026 earnings call. Key numbers: PDUFA date March 3, 2027. Why it matters: Management framed zanzalintinib as the company's second franchise molecule and the next growth driver, with continued expansion beyond current pivotal work.
Exelixis outlined a March 3, 2027 PDUFA date for zanzalintinib while advancing Wave 2 pivotal plans, per its Q3 2026 earnings call.
Management framed zanzalintinib as the company's second franchise molecule and the next growth driver, with continued expansion beyond current pivotal work.
Sources